Literature DB >> 7396451

Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination.

C W Norden, E Keleti.   

Abstract

Rifampin and trimethoprim were used alone and in combination in the treatment of chronic osteomyelitis due to Staphylococcus aureus in rabbits. Rifampicin levels in infected bone were well above the minimum inhibitory concentration of the infecting strain of S. aureus for at least 4 h after injection. In contrast, trimethoprim levels in diseased bone were below the minimum inhibitory concentration as early as 1 h after injection. Trimethoprim or rifampin, administered alone for 14 days, were ineffective in sterilizing infected rabbit bones. The combination of rifampin plus trimethoprim was significantly more effective (P less than 0.005) than either agents given alone for a comparable duration of time. Staphylococci isolated from the bones of rabbits treated with rifampin alone or rifampin plus trimethoprim were uniformly resistant to rifampin, but retained their susceptibility to trimethoprim.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396451      PMCID: PMC283836          DOI: 10.1128/AAC.17.4.591

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Antagonistic interaction of rifampicin and trimethoprim.

Authors:  R J Harvey
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

2.  Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood.

Authors:  L Verbist; A Gyselen
Journal:  Am Rev Respir Dis       Date:  1968-12

3.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

4.  Experimental osteomyelitis. I. A description of the model.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

5.  Interaction between rifampicin and trimethoprim.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1979-01       Impact factor: 5.790

6.  Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

7.  Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

8.  Experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; E Keleti
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

  8 in total
  6 in total

1.  Antimicrobial therapy for bone and joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 2.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

3.  Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).

Authors:  A Stein; J F Bataille; M Drancourt; G Curvale; J N Argenson; P Groulier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

4.  Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.

Authors:  Jagath L Kadurugamuwa; Lin V Sin; Jun Yu; Kevin P Francis; Richard Kimura; Tony Purchio; Pamela R Contag
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus.

Authors:  D R Moorman; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

Review 6.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.